Semaglutide Patient Safety Updates
US$ 29.62
glp-1 agonists weight loss drugs market Size, Share & Trends Analysis by Drugs (Semaglutide (Wegovy), Tirzepatide (Zepbound)), Route of Administration, Distribution Channel, and Region with Growth Forecasts, 2025-2030 GLP-1 Drug Market: the rapid
Description
Am J Obstet Gynecol
Malone, J
13 International Classification of Diseases, Tenth Revision (ICD-10) codes were used to identify annual presence of BD (F30-F31), MDD (F32-F33), T2DM (E11), obesity (E66.0, E66.8, E66.9, Z68.30-Z68.39), stroke (I63), all diabetes (E08-E13), myocardial infarction (I21), obstructive sleep apnea (G47.33), chronic kidney disease (N18), and metabolic dysfunctionassociated steatohepatitis (K75.81)
Association between exposure to GLP-1 receptor agonists and risk of suicide-related and self-harm-related events | HMA-EMA Catalogues of real-world data sources and studies [Internet]
doi: 10.2215/CJN.02560607